Invivyd (IVVD) Total Non-Current Liabilities (2020 - 2024)
Invivyd's (IVVD) quarterly Total Non-Current Liabilities came in at $62.0 million in Q4 2024, up 21.49% YoY from $51.0 million in Q1 2024, and down 21.31% on a QoQ basis from $78.8 million in Q3 2024.
Invivyd (IVVD) Total Non-Current Liabilities (2020 - 2024) Analysis & Trends
Invivyd (IVVD) has 5 years of Total Non-Current Liabilities data on file, last reported at $62.0 million in Q4 2024.
- Quarterly Total Non-Current Liabilities rose 21.49% year-over-year to $62.0 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $62.0 million (up 21.49% YoY) and the FY2024 annual result came in at $62.0 million, up 21.49% from the prior year.
- Total Non-Current Liabilities slipped to $62.0 million in Q4 2024, from $78.8 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $96.9 million in Q1 2022 to a low of $13.1 million in Q4 2020.
- A 5-year average of $50.8 million and a median of $49.2 million in 2022 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Non-Current Liabilities jumped 374.4% — and 2022, when it sank 56.18%.
- Tracing IVVD's Total Non-Current Liabilities over 5 years: stood at $13.1 million in 2020, then jumped by 374.4% to $62.1 million in 2021, then sank by 56.18% to $27.2 million in 2022, then surged by 87.57% to $51.0 million in 2023, then grew by 21.49% to $62.0 million in 2024.
- The last three Total Non-Current Liabilities figures came in at $62.0 million (Q4 2024), $78.8 million (Q3 2024), and $36.7 million (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Invivyd | 212.23 Mn | 52.15 Mn | 13.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 61.98 Mn |
| Sep 30, 2024 | 78.76 Mn |
| Jun 30, 2024 | 36.70 Mn |
| Mar 31, 2024 | 36.97 Mn |
| Dec 31, 2023 | 51.01 Mn |
| Sep 30, 2023 | 27.72 Mn |
| Dec 31, 2022 | 27.20 Mn |
| Sep 30, 2022 | 47.30 Mn |
| Jun 30, 2022 | 69.77 Mn |
| Mar 31, 2022 | 96.88 Mn |
| Dec 31, 2021 | 62.07 Mn |
| Dec 31, 2020 | 13.08 Mn |